SUZANNE BILE: Open Payments
NPI 1265913024 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,035 in 33 payments from 11 companies in 2025. Trend: 2023 $144 · 2024 $997 · 2025 $1,035
Food & beverage: $1,035
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 9 | $291 |
| Lundbeck LLC | 7 | $174 |
| ABBVIE INC. | 5 | $141 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $141 |
| Janssen Pharmaceuticals, Inc | 2 | $68 |
| Alkermes, Inc. | 2 | $59 |
| Vanda Pharmaceuticals Inc. | 2 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $35 |
| E.R. Squibb & Sons, L.L.C. | 1 | $34 |
| Axsome Therapeutics, Inc. | 1 | $20 |
Products named: REXULTI, VRAYLAR, CAPLYTA, ABILIFY ASIMTUFII, LYBALVI, FANAPT, INVEGA SUSTENNA, TRINTELLIX.
Industry payments across NY — which companies pay providers there.
